Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration

Biomarkers in Medicine

Volumn 2, Issue 5, 2008, Pages 465-478

  Fasano, Mauro ^a   Alberio, Tiziana ^a   Lopiano, Leonardo ^b  

^a Department of Structural Functional Biology ^*  (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

synuclein; Biomaker discovery; Parkinson's disease; Peripheral blood lymphocytes; Proteomics

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; BROMOCRIPTINE; CYTOKINE; DJ 1 PROTEIN; DOPAMINE RECEPTOR; HEAT SHOCK PROTEIN 70; HLA DR ANTIGEN; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; PARKIN; UBIQUITIN THIOLESTERASE;

CLINICAL FEATURE; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; HUMAN; METABOLOMICS; MOLECULAR BIOLOGY; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PREVALENCE; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEOMICS; REVIEW;

EID: 59949104645     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.5.465     Document Type: Review

References (135)

1. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
2. Eriksen JL, Wszolek Z, Petrucelli L: Molecular pathogenesis of Parkinson disease. Arch. Neurol. 62, 353-357 (2005).
3. Wood-Kaczmar A, Gandhi S, Wood NW: Understanding the molecular causes of Parkinson's disease. Trends Mol. Med. 12, 521-528 (2006).
4. Olanow CW: The pathogenesis of cell death in Parkinson's disease: 2007. Mov. Disord. 22(Suppl. 17), S335-S342 (2007).
5. Thomas B, Beal MF: Parkinson's disease. Hum. Mol. Genet. 16(Spec. No. 2), R183-R194 (2007).
6. Jankovic J: Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79. 368-376 (2008).
7. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: α-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
8. Gasser T: Update on the genetics of Parkinson's disease. Mov. Disord. 22(Suppl. 17), S343-S350 (2007).
9. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K: Stages in the development of Patkinson's disease-related pathology. Cell Tissue Res. 318, 121-134 (2004).
10. Lotharius J, Brundin P: Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci. 3, 932-942 (2002).
11. Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A: Genetics of Parkinson's disease and parkinsonism. Ann. Neurol. 60, 389-398 (2006).
12. Bonifati V: Genetics of parkinsonism. Parkinsonism Relat. Dipord. 13, S233-S241 (2007).
13. Payami H, Zareparsi S. James D, Nutt J: Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch. Neurol. 59, 848-850 (2002).
14. Lücking CB, Dürr A, Bonicati V et al.: Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342, 1560-1567 (2000).
15. Polymeropoulos MH, Lavedan C, Leroy E et al.: Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
16. Krüger R. Kuhn W, Muller T et al.: Ala30Pro mutation in the gene encoding α-synuclein in Parkinsons disease. Nat. Genet. 18. 106-108 (1998).
17. Zarranz JJ, Alegre J, Gomez-Esteban JC et al.: The new mutation. E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (2004).
18. Chartier-Harlin MC, Kachergus J. Roumier C et al.: α-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004).
19. Ibanez P, Bonnet AM, Debarges B et al.: Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171 (2004).
20. Singleton AB, Farrer M. Johnson J et al.: α-synuclein locus triplication causes Parkinson's disease. Science 302(5646), 841 (2003).
21. Farrer M, Kachergus J, Forno L et al.: Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol. 55, 174-179 (2004).
22. Ischiropoulos H, Beckman JS: Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J. Clin. Invest. 111, 163-169 (2003).
23. Maguire-Zeiss KA, Short DW, Federoff HJ: Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease? Brain Res. Mol. Brain Res. 134, 18-23 (2005).
24. Colapinto M, Mila S, Giraudo S et al.: α-synuclein protects SH-SY5Y cells from dopamine toxicity. Biochem. Biophys. Res. Commun. 349(4), 1294-1300 (2006).
25. Fasano M, Bergamasco B, Lopiano L: The proteomic approach in Parkinson's disease. Proteomics Clin. Appl. 1, 1428-1435 (2007).
26. Fasano M, Lopiano, L: α-synuclein and Parkinson's disease: a proteomic view. Expert Rev. Proteomics 5, 239-248 (2008).
27. Fasano M, Alberio T, Colapinto M, Mila S, Lopiano L: Proteomics as a tool to investigate cell models for dopamine toxicity. Parkinsonism Relat. Disord. 14, S135-S138 (2008).
28. Greenamyre JT, Hastings TG: Biomedicine. Parkinson's: divergent causes, convergent mechanisms. Science 304, 1120-1122 (2004).
29. Betarbet R, Sherer TB, Greenamyre JT: Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 (Suppl. 1), S17-S27 (2005).
30. Przedborski S: Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat. Disord. 11 (Suppl. 1), S3-S7 (2005).
31. Betarbet R, Canet-Aviles RM, Sherer TB et al.: Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22, 404-420 (2006).
32. McNaught KS, Olanow CW: Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol. Aging 27, 530-545 (2006).
33. Barnham KJ, Masters CL, Bush AI: Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Disc. 3, 205-214 (2004).
34. Berg D, Youdim MB, Riederer P: Redox imbalance. Cell Tizue Res. 318, 201-213 (2004).
35. Fasano M, Bergamasco B, Lopiano L: Modifications of the iron-neuromelanin system in Parkinson's disease. J. Neurochem. 96, 909-916 (2006).
36. Fasano M, Bergamasco B, Lopiano L: Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies. J. Neural Transm. 113, 769-774 (2006).
37. Jankovic J, McDermott M, Carter J et al.: Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 40, 1529-1534 (1990).
38. Roos RA, Jongen JC, van der Velde EA: Clinical course of patients with idiopathic Parkinson's disease. Mov. Disord. 11, 236-242 (1996).
39. Shulman LM, Gruber-Baldini AL, Anderson KE et al.: The evolution of disability in Parkinson disease. Mov. Disord. 23, 790-796 (2008).
40. Jellinger KA: Post mortem studies in Parkinson's disease: is it possible to detect brain areas for specific symptoms? J. Neural Transm. Suppl. 56, 1-29 (1999).
41. Lewis SJG, Foltynie T. Blackwell AD, Robbins TW, Owen AM, Barker RA: Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J. Neurol. Neurosurg. Psychiatr. 76, 343-348 (2005).
42. Spiegel J, Hellwig D, Samnick S et al.: Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J. Neural Transm. 114, 331-335 (2007).
43. Allcock LM, Kenny RA, Burn DJ: Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: autonomic symptom and demographic comparison. Mov. Disord. 21, 1851-1855 (2006).
44. Michell AW, Lewis SJG, Foltynie T, Barker RA: Biomarkers and Parkinson's disease. Brain 127, 1693-1705 (2004).
45. Bogdanov M, Matson WR, Wang L et al.: Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131(Pt 2), 389-396 (2008).
46. Bonuccelli U, Del Dotto P: New pharmacologic horizons in the treatment of Parkinson disease Neurology 67(7 Suppl. 2), S30-S38 (2006).
47. Li QX, Mok SS, Laughton KM et al.: Plasma α-synuclein is decreased in subjects with Parkinson's disease. Exp. Neurol. 204, 583-588 (2007).
48. Borghi R, Marchese R, Negro A et al.: Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287. 65-67 (2000).
49. El-Agnaf OM, Salem SA, Paleologou KE et al.: α-synuclein implicated in Parkinson's disease is present in extracellular biological fluids. including human plasma. FASEB J. 17(13), 1945-1947 (2003).
50. Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS: α-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 170, 47-59 (2005).
51. Lee HJ, Patel S, Lee SJ: Intravesicular localization and exocytosis of α-synuclein and its aggregates. J. Neurosci. 25, 6016-6024 (2005).
52. Kaufmann H, Nahm K, Purohit D, Wolfe D: Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63, 1093-1095 (2004).
53. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F et al.: Do α-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 68(23), 2012-2018 (2007).
54. Abbott RD, Petrovitch H, White LR et al.: Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57(3), 456-462 (2001).
55. Michell AW, Luheshi LM, Barker RA: Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci. Lett. 381, 294-298 (2005).
56. Li QX, Campbell BC, McLean CA et al.: Platelet α- and γ-synucleins In Parkinson's disease and normal control subjects. J. Alzheimers Dis. 4(4), 309-315 (2002).
57. Tamo W, Imaizumi T, Tanji K et al.: Expression of α-synuclein, the precursor of non-amyloid β-component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neurosci. Lett. 326, 5-8 (2002).
58. Kim S, Jeon BS, Heo C et al.: α-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J. 18, 1615-1617 (2004).
59. Borro M, Gentile G, Stigliano A, Misiti S, Toscano V, Simmaco M: Proteomic analysis of peripheral T lymphocytes, suitable circulating biosensors of strictly related diseases. Clin. Exp. Immunol. 150. 494-501 (2007).
60. Jeong HC, Lee SY, Lee EJ et al.: Proteomic analysis of peripheral T-lymphocytes in patients with asthma. Chest 132, 489-496 (2007).
61. Wersinger C, Sidhu A: Inflammation and Parkinson's disease. Curr. Drug Targets Inflamm. Allergy 1, 221-242 (2002).
62. Kuhn W, Müller T, Nastos I, Poehlau D: The neuroimmune hypothesis in Parkinson's disease. Rev. Neurosci. 8, 29-34 (1997).
63. Miller DW, Hague SM, Clarimon J et al.: (α-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835-1838 (2004).
64. Miller DW, Crawley A, Gwinn-Hardy K et al.: Unaltered α-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. Neurosci. Lett. 374, 189-191 (2005).
65. Tokuda T, Salem SA, Allsop D et al.: Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166 (2006).
66. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 17, 427-442 (1967).
67. Bonifati V, Rizzu P, van Baren MJ et al.: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2002).
68. Martinat C, Shendelman S, Jonason A et al.: Sensitivity to oxidative stress in DJ-1- deficient dopamine neurons: an ES-derived cell model of primary Parkinsonism. PLoS Biol. 2, e327 (2004).
69. Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A: DJ-1 is a redox-dependent molecular chaperone that inhibits α-synuclein aggregate formation. PLoS Biol. 2, e362 (2004).
70. Waragai M, Wei J, Fujita M et al.: Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345, 967-972 (2006).
71. Batelli S, Albani D, Rametta R et al.: DJ-1 modulates α-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70. PLoS ONE 3, e1884 (2008).
72. Waragai M, Nakai M, Wei J et al.: Plasma levels of DJ-1 as a possible market for progression of sporadic Parkinson's disease Neurosci. Lett. 425, 18-22 (2007).
73. Maita C, Tsuji S, Yabe I et al.: Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 431, 86-89 (2008).
74. Choi J, Sullards MC, Olzmann JA et al.: Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J. Biol. Chem. 281(16), 10816-10824 (2006).
75. Czonkowska A, Kurkowska-Jastrzebska I, Czonkowski A, Peter D, Stefano GB: Immune processes in the pathogenesis of Parkinson's disease: a potential role for microglia and nitric oxide. Med. Sci. Monit. 8(8), RA165-RA177 (2002).
76. McGeer PL, McGeer EG: Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10(Suppl. 1), S3-S7 (2004).
77. Sawada M, Imamura K, Nagatsu T: Role of cytokines in inflammatory process in Parkinson's disease. J. Neural Transm. Suppl. 70, 373-381 (2006).
78. Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150, 963-976 (2007).
79. Stypua G, Kunert-Radek J, Stepie H, Zyliska K, Pawlikowski M: Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation 3, 131-134 (1996).
80. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW: Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100, 34-41 (1999).
81. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A: Peripheral Inflammatory biomarkers and risk of Parkinson's disease. Am. J. Epidemiol. 167(1), 90-95 (2008).
82. Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T: Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 46(3), 791-795 (1996).
83. Barbanti P, Fabbrini G, Ricci A et al.: Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov. Disord. 14(5), 764-771 (1999).
84. 11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-clopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 44, 1325-1329 (1994).
85. Pellicano C, Buttarelli FR, Circella A et al.: Dopomine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J Neural. Transm. 114(7), 935-938 (2007).
86. 123I]-FP-CIT study group. Mov. Disord. 15, 503-510 (2000).
87. Caronti B, Antonini G, Calderaro C et al.: Dopamine transporter Immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural. Transm. 108(7). 803-807 (2001).
88. Ichibangase T, Saimaru H, Takamura N et al.: Proteomics of Caenorhabditis elegans over-expressing human α-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Biomed. Chromatogr. 22(3), 232-234 (2008).
89. Xun Z, Sowell RA, Kaufman TC, Clemmer DE: Protein expression in a Drosophila model of Parkinson's disease. J. Proteome Res. 6, 348-357 (2007).
90. Xun Z, Sowell RA, Kaufman TC, Clemmer DE: Lifetime proteomic profiling of an A30P α-synuclein Drosophila model of Parkinson's disease. J. Proteome Res. 6, 3729-3738 (2007).
91. Xun Z, Sowell RA, Kaufman TC, Clemmer DE: Quantitative proteomics of a presymptomatic A53T α-synuclein Drosophila model of Parkinson's disease. Mol. Cell. Proteomics 7, 1191-1203 (2008).
92. Underwood BR, Broadhurst D, Dunn WB et al.: Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129. 877-886 (2006).
93. Holmes E, Tsang TM, Huang JT et al.: Metabolic profiling of CSF: evidence that early Intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3(8), e327 (2006).
94. Kikuchi A, Takeda A, Onodera H et al.: Systemic increase of oxidative nucleic acid damage in Parkinsons disease and multiple system atrophy. Neurobiol. Dis. 9, 244-248 (2002).
95. Sato S, Mizuno Y, Hattori N: Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64, 1081 1083 (2005).
96. Weisskopf MG, O'Reilly E. Chen H. Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson's disode, Am. J. Epidemiol. 166, 561-567 (2007).
97. Younes-Mhenni S. Frih-Ayed M. Kerkeni A. Bost M, Chazot G: Peripheral blood markers of oxidative stress in Parkinsons disease. Eur Neurol. 58, 78-83 (2007).
98. Schemer CR. Eklund AC. Morse LJ et al.: Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl Acad. Sci. USA 104, 955-960 (2007).
99. Hennecke G, Scherzer C R: RNA biomarkers of Parkinsons disease: developing tools for novel therapies. Biomarkers Med. 2, 41-53 (2008).
100. Recchia A, Debetto P, Negro A. Guirolin D. Skaper SD, Giusti P: α-synuclein and Parkinson's disease. FASEB J. 18(6), 617-626 (2004).
101. Volles MJ, Lee SJ. Rochet JC et al.: Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819 (2001).
102. Volles MJ. Lansbury PT Jr: Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602 (2002).
103. Lashuel HA, Petre BM, Wall J et al.: α-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322(5), 1089-1102 (2002).
104. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr: Kinetic stabilation of the α-synuclein protofibril by a dopamine-α-synuclein addure- Science 294. 1346-1349 (2001).
105. Rochet JC, Outeiro TF, Conway KA et al.: Interactions among α-synucleln. dopamine. and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23. 23-24 (2004).
106. Fasano M. Giraudo S. Coha S, Bergamasco B. Lopiano L: Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to α-synuclein. Neurochem. Int. 42(7). 603-606 (2003).
107. Calvin JE: Interaction of α-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol. 112. 115-126 (2006).
108. Fansohoff RM. Kivisakk P. Kidd G: Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3(7). 569-581 (2003).
109. Kipnis J, Cohen H. Cardon M, Ziv Y, Schwariz M: T cell deficiency leads to cognitive dysfunction: Implications for therapeutic vaccination for schizophrenia and other psychiatric conditions. Proc. Natl Acad. Sci. USA 101 (21), 8180-8185 (2004).
110. Cohen IR. Schwartz M: Autoimmune maintenance and neuroprotection of the central nervous system. J. Neuroimmunol. 100(1-2). 111-114 (1999).
111. Schwartz M: Beneficial autoimmune T cells and posttraumatic neuroprotection. Ann. NY Acad. Sci. 917, 341-347 (2000).
112. Schwartz M Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders. Cell. Mol. Neurobiol. 21(6). 617-627 (2001).
113. Fiszer U: Does Parkinson's disease have an immunological basis? The evidence and Its therapeutic Implications. BioDrugs 15, 351-355 (2001).
114. Martignoni E, Blandini F, Godi L et al.: Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA. Free-Radic. Biol. Med. 27, 428-437 (1999).
115. Migliore L, Petrozzi L. Lucetti C et al.: Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58, 1809-1815 (2002).
116. Blandini F, Manglagalli A, Cosentino M et al.: Peripheral markers of apoptosis In Parkinson's disease: the effect of dopaminergic drugs. Ann. NY Acad. Sci. 1010, 675-678 (2003).
117. Blandini F, Sinforiant E, Pacchetti C et al.: Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66, 529-534 (2006).
118. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T: Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 11 (8), 493-498 (2005).
119. Jimenez Del Rio M. Moreno S, Garcia-Ospina G et al.: Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis. Mov. Disord. 19, 324-330 (2004).
120. Battisti C, Formichi P, Radi E, Federico A: Oxidative-stress-induced apoptosis in PBLs of two patients with Parkinson disease secondary to α-synuclein mutation. J. Neurol. Sci. 267, 120-124 (2008).
121. Jankovic J. Chen S, Le WD: The role of Nurrl in the development of dopaminergic neurons and Parkinson's disease. Prog. Neurobiol. 77, 128-138 (2005).
122. Bergquist J, Tarkowski A, Ekman R, Ewing A: Discovery of endogenous catecholamines In lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc. Natl Acad Sci. USA. 91, 12912-12916 (1994).
123. Marino F, Cosentino M, Bombelli R, Ferrari M, Lecchini S, Frigo G: Endogenous catecholamine synthesis, metabolism storage, and uptake in human peripheral blood mononuclear cells. Exp. Hematol. 27, 489-495 (1999).
124. Cosentino M, Marino F. Bombelli R, Ferrari M. Lecchini S, Frigo G: Unravelling dopamine (and catecholamine) physiopharmacology in lymphocytes: open questions. Trends Immunol. 24, 581-582 (2003).
125. + regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109, 632-642 (2007).
126. Amenta F, Bronzetti E, Cantalamessa F et al.: Identification of dopamine plasma membrane and vesicular transporters In human peripheral blood lymphocytes. J Neuroimmunol. 117, 133-142 (2001).
127. Marazziti D, Baroni S, Dell'Osso MC et al.: Presence and characterization of the dopamine transporter in human resting lymphocytes. Neurochem. Res. 33(6), 1011-1016 (2008).
128. Hanash S: Disease proteomics. Nature 422, 226-232 (2003).
129. Tao WA, ALbersold R: Advances in quantitative proteomics via stable isotope tagging and mass spectrometry Curr. Opin. Biotechnol. 14, 110-118 (2003).
130. Wasinger VC, Cordwell SJ, Cerpa-Poijak A et al.: Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16, 1090-1094 (1995).
131. Lee MP: Genome-wide analysis of epigenetics in cancer. Ann. NY Acad. Sci. 983, 101-109 (2003).
132. Becker M, Schindler J, Nothwang HG: Neuroproteomics: the tasks lying ahead. Electrophoresis 27, 2819-2829 (2006).
133. Sheta EA, Appel SH, Goldknopf IL: 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert Rev. Proteomics 3, 45-62 (2006).
134. Schulenborg T, Schmidt O, van Hall A, Meyer HE, Hamacher M, Marcus K: Proteomics in neurodegeneration: disease driven approaches. J. Neural Transm. 113, 1055-1073 (2006).
135. Dorsey ER, Holloway RG, Ravina BM: Biomarkers in Parkinson's disease. Expert Rev. Neurother. 6, 823-831 (2006).